Severe COVID-19 Outcomes for MS Patients Linked to Several Factors
The results echo the previous understanding of MS specialists as well as add to the literature that has been collected thus far from other assessments.
Related Articles
Lenard A. Adler, MD: “Symptoms of ADHD Need to Go Back to Childhood”
In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when…
Jason Busse, DC, PhD: Do Cannabis, Opioids have a Role in Chronic Pain Management?
Jason Busse, DC, PhD, highlights the modest benefits of opioids and therapeutic cannabis in managing chronic pain.
Patients Help Develop Digital Health App to Improve Fibromyalgia-like Symptoms in Long COVID
These findings can be used to enhance usability of the digital health app and improve outcomes and quality of life among patients with long COVID.
Coordinated Approach with Dermatologists, Internists Leads to Improvement in Psoriasis
These data suggest that a multidisciplinary clinic approach results in several benefits including reduced risk of cardiovascular events among those with psoriasis.
Study Highlights Global Disparities in HBV Evaluation, Treatment
Results suggest chronic hepatitis B virus is globally underassessed and undertreated, especially among women and Asian minorities in the West.
Ruxolitinib Cream Shows Long-Term Disease Control, Efficacy Among Adolescents with Eczema
These data highlight the safety, efficacy, and long-term disease control results of treatment with topical ruxolitinib for a subpopulation of adolescents with atopic dermatitis.
Lenard A. Adler, MD: “Symptoms of ADHD Need to Go Back to Childhood”
In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when…
Navigating ACR’s RA Treatment Guidelines, with Bryant England, MD, PhD
These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.
New Cardiomyopathy Guidelines Endorse Cardiac Myosin Inhibitors, Expanded Role for Exercise
Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.
Ruxolitinib Cream Shows Long-Term Disease Control, Efficacy Among Adolescents with Eczema
These data highlight the safety, efficacy, and long-term disease control results of treatment with topical ruxolitinib for a subpopulation of adolescents with atopic dermatitis.